Comprehensive Analysis of Survodutide Peptide Product
I. Introduction
Survodutide is a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist with a unique mechanism of action, which has attracted significant attention in the field of metabolic disease treatment. It is developed to more effectively address metabolic-related diseases such as obesity, diabetes, and non-alcoholic steatohepatitis (NASH), bringing new therapeutic hope to patients. Different from traditional single-target drugs, it can activate two key receptors simultaneously, exerting a synergistic effect to achieve better therapeutic outcomes.
II. Mechanism of Action
1. GLP-1R Activation: GLP-1R is widely distributed in the central nervous system and peripheral tissues. After Survodutide activates GLP-1R, it can delay gastric emptying, prolong the residence time of food in the stomach, and reduce the rapid rise of postprandial blood glucose. At the same time, it can suppress appetite, reduce the body's desire for food, and decrease energy intake, thereby helping to reduce body weight and control blood glucose levels.
2. GCGR Activation: GCGR is mainly expressed in hepatocytes. When activated by Survodutide, it can increase energy expenditure, such as promoting hepatic fatty acid oxidation to break down and convert fat in the liver into energy; promoting hepatic glycogenolysis and gluconeogenesis to regulate blood glucose levels; reducing cholesterol, decreasing triglyceride synthesis, improving liver metabolism, and greatly benefiting liver health; it can also increase glomerular filtration and water reabsorption, reduce gastrointestinal peristalsis, and indirectly promote fat decomposition in adipose tissue. The combined effect of activating the two receptors not only acts on weight management but also exerts a comprehensive regulatory effect on metabolic indicators such as blood glucose and blood lipids.
III. Clinical Trial Performance
1. Obesity Treatment: In a 46-week randomized, double-blind, placebo-controlled phase 2 clinical trial, 387 non-diabetic individuals with a BMI ≥ 27 kg/m² were enrolled. The subjects were randomly divided into groups receiving weekly subcutaneous injections of Survodutide (0.6, 2.4, 3.6, or 4.8 mg) or a placebo group. The results showed that after 46 weeks of treatment, the body weight of the Survodutide treatment group decreased in a dose-dependent manner, with a 14.9% reduction in body weight compared to the baseline in the 4.8 mg group, while the placebo group only had a 2.8% reduction. Moreover, the proportions of patients in the Survodutide 4.8 mg group with weight reductions of ≥ 5%, ≥ 10%, and ≥ 15% were 82.8%, 68.8%, and 54.7% respectively, which were much higher than 25.9%, 11.1%, and 5.6% in the placebo group. In addition, the Survodutide group also showed more significant effects in terms of absolute changes in body weight and waist circumference reduction, especially in female subjects and those with a lower baseline BMI.
2. Type 2 Diabetes Management: Although large-scale clinical data specifically for type 2 diabetes have not been fully disclosed, based on its mechanism of action, activating GLP-1R can promote insulin secretion and lower blood glucose, and the activation of GCGR can also assist in blood glucose regulation from the perspective of energy metabolism. Theoretically, it has a positive effect on blood glucose control, weight management, and improvement of insulin resistance in patients with type 2 diabetes, and relevant research is still ongoing.
3. Non-Alcoholic Steatohepatitis (NASH) Treatment: A multinational, double-blind, phase II clinical trial (NCT04771273) enrolled 295 patients aged 18-80 years, with biopsy-confirmed MASH (non-alcoholic fatty liver disease activity score NAS ≥ 4), liver fibrosis (stage F1-F3), and a body mass index (BMI) ≥ 25 kg/m². The patients received weekly subcutaneous injections of placebo or Survodutide 2.4 mg, 4.8 mg, or 6.0 mg (with dose titration within 24 weeks). The results showed that at week 48, the proportions of patients in the Survodutide 2.4 mg, 4.8 mg, and 6.0 mg treatment groups who achieved the primary endpoint (histological improvement of MASH without worsening of fibrosis) were 64.3%, 83.0%, and 65.9% respectively, compared with 18.2% in the placebo (PBO) group. After 48 weeks of Survodutide treatment, up to 50.0% of patients with stage F1, F2, and F3 fibrosis achieved significant improvement in liver fibrosis without worsening of MASH, while the improvement rate in the PBO group was 21.2%. Subgroup analysis showed that compared with 25.9% in the placebo group, up to 64.5% of patients with stage F2-F3 fibrosis who received Survodutide treatment achieved fibrosis improvement without worsening of MASH after 48 weeks of treatment.
IV. Safety and Tolerability
In various clinical trials, the safety profile of Survodutide is similar to that of GLP-1 receptor agonists. The most common adverse events are gastrointestinal reactions, such as nausea, vomiting, and diarrhea. In the phase 2 clinical trial for obesity treatment, the incidence of adverse events in the Survodutide treatment group and the placebo group was 90.9% (ranging from 89.7% to 92.2% across different dose groups) and 75.3% respectively, mainly gastrointestinal reactions. In the NASH treatment trial, the incidence of adverse events in the Survodutide treatment group was similar to that in the placebo group, with only a difference in gastrointestinal adverse events (84.9%-87.8% in the Survodutide group vs. 56.8% in the placebo group). However, overall, most patients have good tolerance to Survodutide, and the rate of treatment discontinuation due to adverse events is within an acceptable range.
V. R&D and Application Prospects
At present, Survodutide has successfully obtained the "Breakthrough Therapy" designation from the U.S. Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) of China. The European Medicines Agency (EMA) has also included it in the Priority Medicines (PRIME) scheme. In addition to the above-completed phase 2 clinical trials, a number of large-scale global phase 3 clinical trials are underway, such as the LIVERAGE™ trial for adult patients with MASH accompanied by stage 2 or 3 liver fibrosis, and the LIVERAGE™ - Cirrhosis trial for adult patients with compensated MASH cirrhosis (stage 4). Both trials have been launched in China. In addition, five phase 3 trials for overweight and obese patients are also in progress. In the future, once Survodutide continues to demonstrate good efficacy and safety in more clinical trials and is approved for marketing, it is expected to occupy an important position in the treatment market of metabolic diseases such as obesity, diabetes, and NASH, providing more effective treatment options for a large number of patients.
Our company is a modern advanced enterprise specializing in production and exportation of APIs, Pharmaceutical intermediates, plant extracts etc. Our products are widely used in medicine, health care products, cosmetics, nutritional supplements and food additives areas. Our factory covers an area of 95 acres, the proposed construction of the plant will be GMP standards, the factory environment clean and tidy, rational layout, with large and medium-sized production workshop and repocessed shop. It is equipped with advanced equipment quality inspection and research center. Those products of both quality and technical content have reached the domestic advanced level. Since its establishment, the company has attached great importance to the team training and technical reform. Our modern production equipment guarantees for a fast and effective production with a superior degree of accuracy throughout the whole production line, everything is done in-house, processing, extraction, packaging and transportation of all links, ensuring maximum quality and efficiency. We are constantly research and development new ingredients and innovative new products, have earned the respect & Admiration from the worldwide customers. After years of continuous development, company has been accumulated rich experience in international trade and customer resources, established a stable customer base and perfect marketing service network. In addition, the company has established long-term technical cooperation with experts and professors from many universities and research institutes in the province.
United States
Ecuador
Bangladesh
